Analyse der Lebensqualität von Patienten mit Osteoidosteom vor und nach Behandlung mittels Radiofrequenzablation

Hintergrund: Ziel dieser Arbeit ist es, die Effektivität der Behandlung von Osteoidosteomen (OO) mittels Radiofrequenzablation (RFA) zu untersuchen. Dabei wird insbesondere die Rezidivrate und die Verbesserung der Lebensqualität durch die Reduktion der Schmerzintensität bewertet. Methodik: Retrospektive Analyse von 26 Patienten nach RFA eines OO und prospektive Analyse von 14 Patienten mittels eines selbstentwickelten Lebensqualität-Fragebogens. Es erfolgte die Aufarbeitung des Fragebogens, der elektronischen Patientenakte und der histopathologischen Befunde. Ergebnisse: Durchschnittlich vergangen 22 Monate zwischen erstem Auftreten von Beschwerden und der ursächlichen Therapie mittels RFA. Nach der RFA zeigte sich eine signifikante Reduktion der Schmerzsymptomatik und damit eine Steigerung der Lebensqualität. Unsere Ergebnisse bestätigen, dass die RFA von OO ein sicheres und effizientes Therapieverfahren ist. Diskussion: Um lange konservative Therapieversuche zu vermeiden und Auswirkungen auf das muskuloskeletale System zu vermindern sollte nach Diagnosestellung eine zeitnahe RFA des OO erfolgen

Nutrient and Soil Losses from the Eighteenmile Creek Watershed

Determination of sources and magnitude of soil and nutrient losses from a watershed is prerequisite to remedial action and essential to making cost-effective land management decisions as it reduces the likelihood of costly miscalculations based on the assumption of soil and nutrient sources and modeling rather than their actual identification. This process enhances the ability of concerned groups to obtain external funding for demonstration and remedial projects. In July 2003, the Niagara County Soil & Water Conservation District (NCSWCD), in conjunction with the Department of Environmental Sciences and Biology at SUNY Brockport, began a monitoring program for Eighteenmile Creek, located in Niagara County, New York. The purpose of the monitoring program was to collect water quality data to quantify the concentration and loading of nutrients and suspended sediments transported from Eighteenmile Creek to Lake Ontario and to evaluate the health of the creek and its impact on Lake Ontario. In addition, the data serve as a database to make informed water quality management decisions including the development of a watershed management plan, and as a benchmark of discharge and nutrient data to measure the success of future remediation efforts. This report, prepared by SUNY Brockport and the Niagara County Soil and Water Conservation District, provides information on the nutrient/sediment monitoring program of Eighteenmile Creek. Included are methodologies, results of the monitoring including documentation on types and amounts of nutrients that may be adversely impacting water quality and the conditions which generate them. Lastly, the report serves as a mechanism of transmittal of results and conclusions to all concerned parties and stakeholders of the Eighteenmile Creek watershed

Characterization and Prioritization of the Watersheds of Niagara County, New York

In recognition of the need to acquire a uniform, organized approach to addressing surface 6 water degradation and given the diverse nature of non-point sources of pollution within the County, the Soil and Water Conservation District formed a committee known as the Niagara County Water Quality Coordinating Committee (WQCC). Since little was known about the environmental status of other major creeks in Niagara County, the WQCC recommended a study to evaluate nutrient and soil loss from 17 watersheds and their creeks. The purpose of the monitoring program was to collect water quality data to quantify the concentration and loading of nutrients and suspended sediments transported from 17 Niagara County Creeks to Lake Ontario and to evaluate the health of the creek and its impact on Lake Ontario. In addition, the data serve as a database to make informed water quality management decisions including the development of a watershed management plan, and as a benchmark of discharge and nutrient data to measure the success of future remediation efforts and to suggest a priority listing of water quality goals

Duration of androgen suppression before radiotherapy for localized prostate cancer: Radiation therapy oncology group randomized clinical trial 9910

Purpose To determine whether prolonged androgen suppression (AS) duration before radiotherapy improves survival and disease control in prostate cancer. Patients and Methods One thousand five hundred seventy-nine men with intermediate-risk prostate cancer were randomly assigned to 8 weeks of AS followed by radiotherapy with an additional 8 weeks of concurrent AS (16 weeks total) or to 28 weeks of AS followed by radiotherapy with an additional 8 weeks of AS (36 weeks total). The trial sought primarily to detect a 33% reduction in the hazard of prostate cancer death in the 28-week assignment. Time-to-event end points are reported for up to 10 years of follow-up. Results There were no between-group differences in baseline characteristics of 1,489 eligible patients with follow-up. For the 8- and 28-week assignments, 10-year disease-specific survival rates were 95% (95% CI, 93.3% to 97.0%) and 96% (95% CI, 94.6% to 98.0%; hazard ratio [HR], 0.81; P = .45), respectively, and 10-year overall survival rates were66%(95% CI, 62.0% to 69.9%) and67%(95% CI, 63.0% to 70.8%; HR, 0.95; P = .62), respectively. For the 8- and 28-week assignments, 10-year cumulative incidences of locoregional progression were 6% (95% CI, 4.3% to 8.0%) and 4% (95% CI, 2.5% to 5.7%; HR, 0.65; P = .07), respectively; 10-year distant metastasis cumulative incidences were 6% (95% CI, 4.0% to 7.7%) and 6% (95% CI, 4.0% to 7.6%; HR, 1.07; P = .80), respectively; and 10-year prostate-specific antigen-based recurrence cumulative incidences were 27% (95% CI, 23.1% to 29.8%) and 27% (95% CI, 23.4% to 30.3%; HR, 0.97; P = .77), respectively. Conclusion Extending AS duration from 8 weeks to 28 weeks before radiotherapy did not improve outcomes. A lower than expected prostate cancer death rate reduced ability to detect a between-group difference in disease-specific survival. The schedule of 8 weeks of AS before radiotherapy plus 8 weeks of AS during radiotherapy remains a standard of care in intermediate-risk prostate cancer

A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.

PURPOSE: Long-term (LT) androgen suppression (AS) with radiation therapy (RT) is a standard treatment of high-risk, localized prostate cancer (PCa). Radiation Therapy Oncology Group 9902 was a randomized trial testing the hypothesis that adjuvant combination chemotherapy (CT) with paclitaxel, estramustine, and oral etoposide plus LT AS plus RT would improve overall survival (OS). METHODS AND MATERIALS: Patients with high-risk PCa (prostate-specific antigen 20-100 ng/mL and Gleason score [GS] ≥ 7 or clinical stage ≥ T2 and GS ≥ 8) were randomized to RT and AS (AS + RT) alone or with adjuvant CT (AS + RT + CT). CT was given as four 21-day cycles, delivered beginning 28 days after 70.2 Gy of RT. AS was given as luteinizing hormone-releasing hormone for 24 months, beginning 2 months before RT plus an oral antiandrogen for 4 months before and during RT. The study was designed based on a 6% improvement in OS from 79% to 85% at 5 years, with 90% power and a 2-sided alpha of 0.05. RESULTS: A total of 397 patients (380 eligible) were randomized. The patients had high-risk PCa, 68% with GS 8 to 10 and 34% T3 to T4 tumors, and median prostate-specific antigen of 22.6 ng/mL. The median follow-up period was 9.2 years. The trial closed early because of excess thromboembolic toxicity in the CT arm. The 10-year results for all randomized patients revealed no significant difference between the AS + RT and AS + RT + CT arms in OS (65% vs 63%; P=.81), biochemical failure (58% vs 54%; P=.82), local progression (11% vs 7%; P=.09), distant metastases (16% vs 14%; P=.42), or disease-free survival (22% vs 26%; P=.61). CONCLUSIONS: NRG Oncology RTOG 9902 showed no significant differences in OS, biochemical failure, local progression, distant metastases, or disease-free survival with the addition of adjuvant CT to LT AS + RT. The trial results provide valuable data regarding the natural history of high-risk PCa treated with LT AS + RT and have implications for the feasibility of clinical trial accrual and tolerability using CT for PCa

Analyse der Lebensqualität von Patienten mit Osteoidosteom vor und nach Behandlung mittels Radiofrequenzablation

Hintergrund: Ziel dieser Arbeit ist es, die Effektivität der Behandlung von Osteoidosteomen (OO) mittels Radiofrequenzablation (RFA) zu untersuchen. Dabei wird insbesondere die Rezidivrate und die Verbesserung der Lebensqualität durch die Reduktion der Schmerzintensität bewertet. Methodik: Retrospektive Analyse von 26 Patienten nach RFA eines OO und prospektive Analyse von 14 Patienten mittels eines selbstentwickelten Lebensqualität-Fragebogens. Es erfolgte die Aufarbeitung des Fragebogens, der elektronischen Patientenakte und der histopathologischen Befunde. Ergebnisse: Durchschnittlich vergangen 22 Monate zwischen erstem Auftreten von Beschwerden und der ursächlichen Therapie mittels RFA. Nach der RFA zeigte sich eine signifikante Reduktion der Schmerzsymptomatik und damit eine Steigerung der Lebensqualität. Unsere Ergebnisse bestätigen, dass die RFA von OO ein sicheres und effizientes Therapieverfahren ist. Diskussion: Um lange konservative Therapieversuche zu vermeiden und Auswirkungen auf das muskuloskeletale System zu vermindern sollte nach Diagnosestellung eine zeitnahe RFA des OO erfolgen

Analyse der Lebensqualität von Patienten mit Osteoidosteom vor und nach Behandlung mittels Radiofrequenzablation

Hintergrund: Ziel dieser Arbeit ist es, die Effektivität der Behandlung von Osteoidosteomen (OO) mittels Radiofrequenzablation (RFA) zu untersuchen. Dabei wird insbesondere die Rezidivrate und die Verbesserung der Lebensqualität durch die Reduktion der Schmerzintensität bewertet. Methodik: Retrospektive Analyse von 26 Patienten nach RFA eines OO und prospektive Analyse von 14 Patienten mittels eines selbstentwickelten Lebensqualität-Fragebogens. Es erfolgte die Aufarbeitung des Fragebogens, der elektronischen Patientenakte und der histopathologischen Befunde. Ergebnisse: Durchschnittlich vergangen 22 Monate zwischen erstem Auftreten von Beschwerden und der ursächlichen Therapie mittels RFA. Nach der RFA zeigte sich eine signifikante Reduktion der Schmerzsymptomatik und damit eine Steigerung der Lebensqualität. Unsere Ergebnisse bestätigen, dass die RFA von OO ein sicheres und effizientes Therapieverfahren ist. Diskussion: Um lange konservative Therapieversuche zu vermeiden und Auswirkungen auf das muskuloskeletale System zu vermindern sollte nach Diagnosestellung eine zeitnahe RFA des OO erfolgen